SciELO - Scientific Electronic Library Online

 
vol.26 issue4Analysis of the waves and aggregation patterns in patients with cardiovascular diseases in using acetylsalicylic acid compared blood donors author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Revista Brasileira de Hematologia e Hemoterapia

Print version ISSN 1516-8484

Abstract

MASSUMOTO, Celso M. et al. Gemtuzumab Ozogamicin: an option in the treatment of acute myeloid leukemia CD33+. Rev. Bras. Hematol. Hemoter. [online]. 2004, vol.26, n.4, pp. 235-238. ISSN 1516-8484.  http://dx.doi.org/10.1590/S1516-84842004000400002.

Gemtuzumab Ozogamicin consists of a semisynthetic derivate of calicheamicin, a cytotoxic antibiotic linked to a recombinant monoclonal antibody directed against the CD33 antigen present on leukemic myeloblasts. The aim of this report is to evaluate the side effects, remission and survival of 11 patients with acute myeloid leukemia that took Gemtuzumab Ozogamicin. The major toxicity was myelosuppression that was seen in all the patients. One patient died due to hepatic veno-occlusive disease. Four patients used the drug for relapse and two achieved partial remission. Two patients used the drug for refractory disease and one achieved complete remission with 12 months survival. Gemtuzumab Ozogamicin was also used for the consolidation therapy of 5 patients. We believe that Gemtuzumab Ozogamicin is safe and is an alternative for patients that do not respond to conventional therapy.

Keywords : Gemtuzumab Ozogamicin; leukemia; therapy.

        · abstract in Portuguese     · text in Portuguese     · pdf in Portuguese